AR065796A1 - Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina - Google Patents
Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidinaInfo
- Publication number
- AR065796A1 AR065796A1 ARP080101144A ARP080101144A AR065796A1 AR 065796 A1 AR065796 A1 AR 065796A1 AR P080101144 A ARP080101144 A AR P080101144A AR P080101144 A ARP080101144 A AR P080101144A AR 065796 A1 AR065796 A1 AR 065796A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorder
- depression
- addition salt
- salt
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Reivindicacion 1: Una formulacion farmacéutica líquida que comprende una sal de 4-[2-(4-metilfenilsulfanil)fenil]piperidina seleccionada entre la sal de adicion de ácido DL-láctico, la sal de adicion del ácido glutárico, la sal de adicion del ácidoL-aspártico y la sal de adicion del ácido glutámico. Reivindicacion 15: Una sal de 4-[2-(4-metilfenilsulfanil)fenil]piperidina seleccionada entre la sal de adicion del ácido DL-láctico, la sal de adicion del ácido glutárico, la sal de adicion delácido L-aspártico y la sal de adicion del ácido glutámico para utilizar en el tratamiento de una enfermedad seleccionada entre trastornos del estado de ánimo, trastorno depresivo mayor, trastorno de ansiedad generalizada, depresion atípica,depresion bipolar, trastorno de ansiedad social, trastorno obsesivo compulsivo, trastorno de pánico, trastorno de estrés post-traumático, abuso, trastorno alimenticio, trastorno del sueno, enfermedad de Alzheimer, demencia, dolor cronico, depresionasociada con deterioro cognitivo, depresion asociada con psicosis, deterioro cognitivo en la esquizofrenia, depresion o ansiedad asociada con dolor, alteraciones del comportamiento en las personas mayores de edad, ADHD, melancolía, depresionresistente al tratamiento o depresion con síntomas residuales, donde dicha sal está en una formulacion farmacéutica líquida.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200700423 | 2007-03-20 | ||
PCT/DK2007/050076 WO2007144006A1 (en) | 2006-06-16 | 2007-06-15 | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
DKPA200701790 | 2007-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065796A1 true AR065796A1 (es) | 2009-07-01 |
Family
ID=39327217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101144A AR065796A1 (es) | 2007-03-20 | 2008-03-19 | Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina |
Country Status (27)
Country | Link |
---|---|
US (1) | US20100105730A1 (es) |
EP (2) | EP2129377B1 (es) |
JP (1) | JP5301474B2 (es) |
KR (1) | KR20090130000A (es) |
AR (1) | AR065796A1 (es) |
AT (1) | ATE526966T1 (es) |
AU (1) | AU2008228637B2 (es) |
BR (1) | BRPI0808820A2 (es) |
CA (1) | CA2684592C (es) |
CL (1) | CL2008000797A1 (es) |
CO (1) | CO6220958A2 (es) |
CY (1) | CY1112285T1 (es) |
DK (1) | DK2129377T3 (es) |
EA (1) | EA019695B1 (es) |
ES (1) | ES2373275T3 (es) |
HK (1) | HK1140949A1 (es) |
HR (1) | HRP20110844T1 (es) |
IL (1) | IL200959A (es) |
MX (1) | MX2009009388A (es) |
MY (1) | MY148695A (es) |
NZ (1) | NZ579717A (es) |
PL (1) | PL2129377T3 (es) |
PT (1) | PT2129377E (es) |
RS (1) | RS52050B (es) |
SI (1) | SI2129377T1 (es) |
TW (1) | TWI405588B (es) |
WO (1) | WO2008113358A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | 4-〔2-(4-甲基苯硫基)苯基〕哌啶之新穎治療用途 |
SI2167085T1 (sl) * | 2007-06-15 | 2014-05-30 | H. Lundbeck A/S | 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs) |
US8940746B2 (en) | 2009-04-24 | 2015-01-27 | H. Lundbeck A/S | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine |
WO2011136373A1 (ja) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
US20130115292A1 (en) | 2010-04-30 | 2013-05-09 | Takeda Pharmaceutical Company Limited | Enteric tablet |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10163326A1 (de) | 2001-07-30 | 2003-02-27 | Disetronic Licensing Ag | Verabreichungsgerät mit Dosiervorrichtung |
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
EP1446328B1 (en) | 2001-10-16 | 2017-05-31 | Medical Instill Technologies, Inc. | DISPENSER WITH SEALED CHAMBER AND ONE−WAY VALVE FOR PROVIDING METERED AMOUNTS OF SUBSTANCES |
DE10202367A1 (de) | 2002-01-23 | 2003-09-25 | Duerr Dental Gmbh Co Kg | Applikator für flüssige oder viskose Substanzen |
MXPA05009592A (es) * | 2003-04-04 | 2005-10-18 | Lundbeck & Co As H | Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inhibidores de recaptacion de serotonina. |
PL2044020T3 (pl) * | 2006-06-16 | 2011-09-30 | H Lundbeck As | Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego |
KR101367136B1 (ko) * | 2007-07-27 | 2014-02-25 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 및 이의 제조 방법 |
-
2008
- 2008-03-06 TW TW097107758A patent/TWI405588B/zh not_active IP Right Cessation
- 2008-03-14 ES ES08715616T patent/ES2373275T3/es active Active
- 2008-03-14 DK DK08715616.2T patent/DK2129377T3/da active
- 2008-03-14 NZ NZ579717A patent/NZ579717A/en not_active IP Right Cessation
- 2008-03-14 RS RS20110545A patent/RS52050B/en unknown
- 2008-03-14 KR KR1020097019519A patent/KR20090130000A/ko active IP Right Grant
- 2008-03-14 PL PL08715616T patent/PL2129377T3/pl unknown
- 2008-03-14 US US12/527,907 patent/US20100105730A1/en not_active Abandoned
- 2008-03-14 SI SI200830435T patent/SI2129377T1/sl unknown
- 2008-03-14 BR BRPI0808820-9A patent/BRPI0808820A2/pt not_active IP Right Cessation
- 2008-03-14 EP EP08715616A patent/EP2129377B1/en active Active
- 2008-03-14 CA CA2684592A patent/CA2684592C/en not_active Expired - Fee Related
- 2008-03-14 JP JP2009553909A patent/JP5301474B2/ja not_active Expired - Fee Related
- 2008-03-14 MX MX2009009388A patent/MX2009009388A/es active IP Right Grant
- 2008-03-14 AT AT08715616T patent/ATE526966T1/de active
- 2008-03-14 AU AU2008228637A patent/AU2008228637B2/en not_active Ceased
- 2008-03-14 WO PCT/DK2008/050062 patent/WO2008113358A1/en active Application Filing
- 2008-03-14 EA EA200970869A patent/EA019695B1/ru not_active IP Right Cessation
- 2008-03-14 PT PT08715616T patent/PT2129377E/pt unknown
- 2008-03-14 EP EP11177654A patent/EP2388004A1/en not_active Withdrawn
- 2008-03-14 MY MYPI20093675A patent/MY148695A/en unknown
- 2008-03-19 AR ARP080101144A patent/AR065796A1/es unknown
- 2008-03-19 CL CL200800797A patent/CL2008000797A1/es unknown
-
2009
- 2009-09-15 IL IL200959A patent/IL200959A/en not_active IP Right Cessation
- 2009-09-16 CO CO09100112A patent/CO6220958A2/es not_active Application Discontinuation
-
2010
- 2010-08-03 HK HK10107411.4A patent/HK1140949A1/xx not_active IP Right Cessation
-
2011
- 2011-11-14 HR HR20110844T patent/HRP20110844T1/hr unknown
- 2011-12-02 CY CY20111101195T patent/CY1112285T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076400A1 (es) | Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente | |
AR065796A1 (es) | Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina | |
Daneshpazhooh et al. | Mucocutaneous findings in 100 children with Down syndrome | |
Carlson et al. | Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation | |
López‐Jornet et al. | A prospective, randomized study on the efficacy of tongue protector in patients with burning mouth syndrome | |
AR065798A1 (es) | Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina | |
HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
UY29924A1 (es) | Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables | |
Park et al. | The analysis of risk factors influencing adolescent suicidal ideation in a multicultural family-based on the 2012 Korean youth health risk behavior on-line survey | |
AR098599A2 (es) | Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo | |
Baruch et al. | Treatment for depression comorbid with dementia | |
Granata | Comprehensive care of children with Dravet syndrome | |
Earle | An introduction to the psychopharmacology of children and adolescents with autism spectrum disorder | |
Kowal et al. | Bilastine as a potential treatment in allergic rhinitis | |
Stringaris | The new DSM is coming-it needs tough love... | |
CA2614731A1 (en) | Multimediator dopamine transport inhibitors, and uses related thereto | |
Paris | Personality disorders and mood disorders: Phenomenological resemblances vs. pathogenetic pathways | |
Bohlmeijer et al. | Positive clinical interventions: Why are they important and how do they work? | |
Sogolitappeh et al. | Effectiveness of group life skills training on decreasing anxiety and depression among heart patients, after bypass surgery | |
Rappa et al. | Condensed psychopharmacology 2013: a pocket reference for psychiatry and psychotropic medications | |
Pontoski et al. | Psychotherapy for social anxiety disorder. | |
Cordero Jr | I will survive!: saving the extroverts through virtual interaction during the COVID-19 pandemic | |
Lan et al. | Nursing Experience of Using Mirror Visual Feedback for a Schizophrenia Patient With Visual Hallucinations | |
BRPI0405989A (pt) | artigo plastificado para tratamento da pele | |
Milev | Book Review: Mood Disorders: Advances in Treatment of Bipolar Disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |